Sustained Response of a Clivus Chordoma to Erlotinib after Imatinib Failure
| Autor: | Aline Houessinon, Patrick Toussaint, Jean-Marc Constans, Bruno Chauffert, Mathieu Boone |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty lcsh:RC254-282 Gefitinib Internal medicine Published online: January 2015 Chordoma medicine Growth factor receptor inhibitor Epidermal growth factor receptor neoplasms EGFR inhibitors biology business.industry Imatinib lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease respiratory tract diseases Erlotinib biology.protein business Clivus Chordoma medicine.drug |
| Zdroj: | Case Reports in Oncology Case Reports in Oncology, Vol 8, Iss 1, Pp 25-29 (2015) |
| ISSN: | 1662-6575 |
| DOI: | 10.1159/000371843 |
| Popis: | Chordoma is a rare malignant axial tumour that develops from embryonic remnants of the notochord. Surgery and irradiation are the standard initial treatment. However, local recurrence is frequent and cytotoxic chemotherapy is inefficient. Transient activity of imatinib, a platelet-derived growth factor receptor inhibitor, was described in a phase II study. Activity of epidermal growth factor receptor (EGFR) inhibitors (erlotinib, gefitinib) has also been shown in a few recent case reports. We describe a 68-year-old female in whom clivus chordoma recurred after surgery and radiotherapy. The tumour progressed despite imatinib treatment. A partial and sustained response (28+ months) was obtained using erlotinib, an EGFR inhibitor. Erlotinib should be evaluated in a prospective trial investigating new potential therapies against recurrent chordoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|